^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    undefined TAA/TSA-targeted antibody-drug conjugate

    Related drugs:
    5ms
    A Study of PHN-010 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=273, Recruiting, Pheon Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open
    6ms
    A Study of PHN-010 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=273, Not yet recruiting, Pheon Therapeutics
    New P1 trial • Metastases
    9ms
    NAPISTAR1-01: FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC (clinicaltrials.gov)
    P1/2, N=100, Not yet recruiting, Tubulis GmbH
    New P1/2 trial
    10ms
    GT-00AxIL15, a Novel Tumor-Targeted IL-15-Based Immunocytokine for the Treatment of TA-MUC1-Positive Solid Tumors: Preclinical In Vitro and In Vivo Pharmacodynamics and Biodistribution Studies. (PubMed, Int J Mol Sci)
    These results support the rationale to improve PK and anti-tumor efficacy of IL-15 by increasing local concentrations at the tumor site via conjugation to a TA-MUC1 binding mAb. The tumor-selective expression pattern of TA-MUC1, powerful immune activation and anti-tumor cytotoxicity, long serum half-life and tumor targeting properties, render GT-00AxIL15 a promising candidate for treatment of solid tumors with high medical need, e.g., ovarian, lung and breast cancer.
    PK/PD data • Preclinical • Journal
    |
    CD8 (cluster of differentiation 8) • MUC1 (Mucin 1) • IL15 (Interleukin 15)
    |
    TA-MUC1 positive
    |
    GT-00A x IL15
    over1year
    Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=200, Recruiting, Shanghai Hengrui Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    SHR-A2102
    almost2years
    Preclinical development of a next generation antibody drug conjugate (ADC) targeting B7-H3 for treatment of solid tumors (AACR 2023)
    Safety evaluations demonstrated acceptable safety profile and no off-target toxicity in monkeys. These non-clinical data suggest the stability of linker in circulation but efficiently release the payload in tumors, and eventually, expanded the therapeutic window.Taken together, preclinical data suggest that YL201 could be a promising treatment strategy for B7-H3 positive cancer patients.
    Preclinical • PARP Biomarker
    |
    CD28 (CD28 Molecule) • CASP7 (Caspase 7)
    |
    PARP1 elevation
    |
    YL201
    2years
    A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer (clinicaltrials.gov)
    P1, N=80, Recruiting, MediLink Therapeutics (Suzhou) Co., Ltd.
    New P1 trial • Metastases
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2)
    |
    EGFR mutation • HR positive • HER-2 negative • EGFR L858R • EGFR exon 19 deletion • HR positive + HER-2 negative
    |
    BNT326